Novo Nordisk updates 2026 outlook after earnings release
AI Market Summary
Novo Nordisk narrowed its 2026 constant-currency guidance but still expects adjusted sales and operating profit to range from -6% to 0% y/y, despite 7% adjusted sales growth in 1H/2Q. The outlook underscores deceleration risk and renews concerns about the durability of GLP-1 demand and competitive pressures. The US-listed shares fell over 5%, likely weighing near-term pharma/obesity-therapy sentiment.
Impact level
● Medium
Affected assets
NCSKNVO2USD/USDT-5.35%
AI Insight · NCSKNVO2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Novo Nordisk issued its 2026 guidance, forecasting adjusted sales to range between -6% and 0% year over year on a constant-currency basis, narrowing from its prior -4% to -12% outlook. The company also revised its adjusted operating profit view to the same -6% to 0% range.
Separately, Novo Nordisk reported adjusted sales growth of 7% year over year for the first half of 2026 and for the second quarter. The update stirred investor concerns about the durability of GLP-1 drug growth, sending the company's U.S.-listed shares down more than 5% on the day.
